Avanir Pharmaceuticals (Nasdaq: AVNR) reported earnings on Dec. 12. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q4), Avanir Pharmaceuticals beat expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share dropped.

Gross margins contracted, operating margins expanded, net margins increased.

Revenue details
 Avanir Pharmaceuticals logged revenue of $13.5 million. The five analysts polled by S&P Capital IQ expected revenue of $13.0 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $4.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.09. The four earnings estimates compiled by S&P Capital IQ predicted -$0.08 per share. GAAP EPS were -$0.09 for Q4 against -$0.14 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 94.7%, 80 basis points worse than the prior-year quarter. Operating margin was -78.9%, 29,890 basis points better than the prior-year quarter. Net margin was -86.6%, 29,120 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $15.4 million. On the bottom line, the average EPS estimate is -$0.08.

Next year's average estimate for revenue is $82.8 million. The average EPS estimate is -$0.30.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 189 members out of 251 rating the stock outperform, and 62 members rating it underperform. Among 56 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Avanir Pharmaceuticals a green thumbs-up, and 17 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is outperform, with an average price target of $5.60.